Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients

Background The host immune response has a prominent role in the progression and outcome of SARS-CoV-2 infection. Lymphopenia has been described as an important feature of SARS-CoV-2 infection and has been associated with severe disease manifestation. Lymphocyte dysregulation and hyper-inflammation have been shown to be associated with a more severe clinical course; however, a T cell subpopulation whose dysfunction correlate with disease progression has yet to be identify. Methods We performed an immuno-phenotypic analysis of T cell sub-populations in peripheral blood from patients affected by different severity of COVID-19 (n=60) and undergoing a different clinical evolution. Clinical severity was established based on a modified WHO score considering both ventilation support and respiratory capacity (PaO2/FiO2 ratio). The ability of circulating cells at baseline to predict the probability of clinical aggravation was explored through multivariate regression analyses. Results The immuno-phenotypic analysis performed by multi-colour flow cytometry confirmed that patients suffering from severe COVID-19 harboured significantly reduced circulating T cell subsets, especially for CD4+ T, Th1, and regulatory T cells. Peripheral T cells also correlated with parameters associated with disease severity, i.e., PaO2/FiO2 ratio and inflammation markers. CD4+ T cell subsets showed an important significant association with clinical evolution, with patients presenting markedly decreased regulatory T cells at baseline having a significantly higher risk of aggravation. Importantly, the combination of gender and regulatory T cells allowed distinguishing between improved and worsened patients with an area under the ROC curve (AUC) of 82%. Conclusions The present study demonstrates the association between CD4+ T cell dysregulation and COVID-19 severity and progression. Our results support the importance of analysing baseline regulatory T cell levels, since they were revealed able to predict the clinical worsening during hospitalization. Regulatory T cells assessment soon after hospital admission could thus allow a better clinical stratification and patient management.

[1]  E. Shin,et al.  SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells , 2021, Nature Communications.

[2]  F. Borrego,et al.  T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19 , 2021, Frontiers in Immunology.

[3]  E. Segala,et al.  ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections , 2021, Genomics.

[4]  S. Mallal,et al.  Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases , 2021, Cell Reports Medicine.

[5]  C. June,et al.  Cytokine Storm , 2020, The New England journal of medicine.

[6]  C. Akdis,et al.  Risk factors for severe and critically ill COVID‐19 patients: A review , 2020, Allergy.

[7]  G. Mosayebi,et al.  Cytokine profile and disease severity in patients with COVID-19 , 2020, Cytokine.

[8]  J. Greenbaum,et al.  Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity , 2020, Cell.

[9]  S. M. Toor,et al.  T‐cell responses and therapies against SARS‐CoV‐2 infection , 2020, Immunology.

[10]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[11]  A. Sattler,et al.  SARS-CoV-2 specific T-cell responses and correlations with COVID-19 patient predisposition. , 2020, The Journal of clinical investigation.

[12]  W. Greene,et al.  SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential , 2020, Cell Reports Medicine.

[13]  Zeyu Chen,et al.  T cell responses in patients with COVID-19 , 2020, Nature Reviews Immunology.

[14]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[15]  Aaron M. Rosenfeld,et al.  Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.

[16]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[17]  C. Agrati,et al.  Immunological and inflammatory profiles in mild and severe cases of COVID-19 , 2020, Nature Communications.

[18]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[19]  U. Qimron Faculty Opinions recommendation of Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[20]  L. García,et al.  Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 , 2020, Frontiers in Immunology.

[21]  M. O'gorman,et al.  Lymphocyte Subset Counts in COVID‐19 Patients: A Meta‐Analysis , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[22]  Mike Clarke,et al.  A minimal common outcome measure set for COVID-19 clinical research , 2020, The Lancet Infectious Diseases.

[23]  M. Ono,et al.  T-Cell Hyperactivation and Paralysis in Severe COVID-19 Infection Revealed by Single-Cell Analysis , 2020, bioRxiv.

[24]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[25]  B. Lipworth,et al.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[26]  Chengliang Zhu,et al.  Decreased T cell populations contribute to the increased severity of COVID-19 , 2020, Clinica Chimica Acta.

[27]  L. Roncati,et al.  Signals of Th2 immune response from COVID-19 patients requiring intensive care , 2020, Annals of Hematology.

[28]  Aiping Le,et al.  T cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of COVID-19 , 2020, The Journal of infectious diseases.

[29]  J. Wolchok,et al.  The many faces of the anti-COVID immune response , 2020, The Journal of experimental medicine.

[30]  G. Gao,et al.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[31]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[32]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[33]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[34]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  T. Kalina,et al.  EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.

[36]  F. Schmidt Meta-Analysis , 2008 .

[37]  Daishi Tian,et al.  Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China , 2020 .

[38]  H. Woodrow,et al.  : A Review of the , 2018 .